46 articles with Taiho Oncology
Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals' Drug Candidates
Taiho Oncology, Inc. announces that it has assumed commercialization responsibility from Otsuka Pharmaceuticals Co., Ltd., (Otsuka) for the novel fixed-dose combination of cedazuridine and decitabine (ASTX727) and guadecitabine (SGI-110) in the U.S. and Canada, subject to regulatory approvals.
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting
Taiho Oncology, Inc. and Servier announced today clinical data with LONSURF® (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer (mGC), metastatic gastroesophageal junction adenocarcinoma (mGEJC) and metastatic colorectal cancer (mCRC) were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Taiho Oncology Announces Support of Colorectal Cancer Awareness Month Through Research and Awareness Initiatives
Taiho Oncology, Inc., in partnership with leading advocacy groups including Colorectal Cancer Alliance, Fight Colorectal Cancer and COLONTOWN®, today announced its support of a number of prevention and awareness initiatives during National Colorectal Cancer Awareness Month.
FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
The approval of LONSURF represents a significant milestone for patients living with advanced gastric or GEJ adenocarcinoma who have limited effective treatment options after standard treatment options have failed.
FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)
Taiho Oncology, Inc. and Servier announced that the safety and efficacy in patients with gastrectomy from the global Phase 3 TAGS trial evaluating LONSURF® in patients with previously treated metastatic gastric cancer (mGC) are consistent with the overall study results published in The Lancet Oncology.
FDA Accepts Supplemental New Drug Application for LONSURF® (trifluridine/tipiracil) for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma; Grants Priority Review
Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted and granted priority review for the supplemental New Drug Application (sNDA) for LONSURF® (trifluridine/tipiracil, TAS-102) as a treatment for patients with previously treated, advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
NCCN Awarded $2 Million in Research Funding from Taiho Oncology to Study Trifluridine and Tipiracil in Various Cancers
The National Comprehensive Cancer Network's Oncology Research Program received a grant to investigate effectiveness of trifluridine and tipiracil for treatment of people with colorectal, gastric, and other cancers
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Results from TAGS Trial Meets Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival in Patients with Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
Taiho Oncology today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib).*
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018
Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)
Taiho's Patient Assistance Programs Commit to Addressing Patient Burden through New Program Enhancements
A phase I multicenter, open-label study examined the maximum tolerated dose of a LONSURF and oxaliplatin combination in patients with mCRC.
Taiho Oncology today announced the promotion of Timothy Whitten from Senior VP and COO to President, effective January 1, 2018.
Taiho Oncology Announces Comprehensive Access Support Program For LONSURF (trifluridine And tipiracil)
Taiho Oncology Announces FDA Approval Of LONSURF (Trifluridine And Tipiracil) For Refractory Metastatic Colorectal Cancer (mCRC)
Taiho Oncology Announces TAS-102 New Drug Application For Refractory Metastatic Colorectal Cancer Accepted For Review By FDA